One way redox cancer therapeutics are thought to perturb this Prx/Trx/TrxR pathway in cancer cells is through inhibition of the reduction pathways that cells used to regenerate reduced antioxidant enzymes, which results in accumulation of oxidized peroxiredoxin species that can participate in signaling reactions9,11. Here, PRX is linked to cancer.